BI-1701963 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BI-1701963’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BI-1701963 is under development for the treatment of KRAS mutated advanced or metastatic solid tumors including lung adenocarcinoma, non-small cell lung cancer, metastatic pancreatic cancer, metastatic cholangiocarcinoma and metastatic colorectal cancer. It is administered through oral route as a film coated tablet. The drug candidate acts by targeting son of sevenless homolog 1 (SOS1).
For a complete picture of BI-1701963’s drug-specific PTSR and LoA scores, buy the report here.